Auditor Raises Going Concern Doubt Amidst Critically Low Cash, Nasdaq Delisting, and Highly Dilutive Financings

summarizeSummary

Brainstorm Cell Therapeutics is in severe financial distress, with its auditor raising going concern doubts due to critically low cash, Nasdaq delisting, and reliance on highly dilutive short-term financings.

check_boxKey Events

• Auditor Raises Going Concern Doubt

  The independent auditor's report explicitly states 'substantial doubt about its ability to continue as a going concern' due to insufficient resources and ongoing operating losses.

• Critically Low Cash Balance

  The company reported a cash and cash equivalents balance of only $29,000 as of December 31, 2025, indicating severe liquidity constraints.

• Nasdaq Delisting and OTCQB Transition

  Brainstorm's common stock was delisted from The Nasdaq Capital Market on July 17, 2025, due to non-compliance with minimum shareholder equity, and now trades on the OTCQB Venture Market.

• Highly Dilutive Short-Term Financings

  The company secured multiple short-term convertible promissory notes in late 2025 and early 2026, totaling approximately $500,000 in net proceeds, with conversion terms including discounts of 25-35% to market price and warrants for 120% of purchased units, signaling distressed financing.

auto_awesomeAnalysis

Brainstorm Cell Therapeutics faces severe financial distress, with its auditor expressing substantial doubt about its ability to continue as a going concern. The company ended 2025 with a critically low cash balance of only $29,000 and has incurred significant operating losses. Following its delisting from Nasdaq in July 2025 due to non-compliance with equity requirements, its stock now trades on the OTCQB Venture Market, further limiting liquidity and financing options. Recent short-term financings, including multiple convertible notes and a private placement, feature highly dilutive terms such as deep discounts to market price and substantial warrant coverage, indicating a desperate need for capital. While the company has made regulatory progress with FDA agreement on a Phase 3b trial design for NurOwn in ALS, its ability to fund this trial and future operations remains highly uncertain. Additionally, the identification of a material weakness in internal controls and ongoing litigation add to the significant operational and financial risks.